Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Edition
European
US
Rheumatology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
The first and only approved dual inhibitor of IL-17A and IL-17F1-6
February 2026
BIMZELX® Demonstrated Deep and Sustained Efficacy to 3 Years Across Multiple Disease Domains of PsA and the Full axSpA Spectrum…
Read more
6 Aug 2018
Genetic Screen Could Predict Risk of Osteoporosis
Osteoporosis and fracture risk could be predicted early on through a genetic screen, following the discovery of 899 regions in the human genome…
31 Jul 2018
European Medical Journal Presents: EMJ Rheumatology 5.1
The European Medical Journal has published the latest edition of EMJ Rheumatology, which includes a full review of the European League Against Rheumatism (EULAR) congress, a selection of peer-reviewed papers, interviews with members of our esteemed editorial board, and much more.
1
Mins
31 Jul 2018
Treating Rheumatoid Arthritis to Target: Is Low Disease Activity Good Enough?
Treat-to-target principles in rheumatoid arthritis (RA) are now widely recognised as effective in achieving optimal disease outcomes. This study examined…
9
Mins
31 Jul 2018
Anti-TNF in Rheumatic Diseases: Inventory and Outlook
With an increasing number of biosimilars receiving regulatory approval, the treatment landscape for rheumatic diseases is evolving. Healthcare…
13
Mins
31 Jul 2018
Review of the 19th European League Against Rheumatology Congress 2018
Almost 20 years have passed since the first annual European League Against Rheumatism (EULAR) Congress took place on the sunny shores of the French…
2
Mins
31 Jul 2018
Physician Global Assessments for Disease Activity in Rheumatoid Arthritis Are All Over the Map!
There have been many studies about patient global assessments of disease activity in rheumatoid arthritis (RA) and how these differ from physician global…
8
Mins
31 Jul 2018
Editor's Pick: JAK Inhibitors in the Treatment Algorithm of Rheumatoid Arthritis: A Review
Biological disease-modifying antirheumatic drugs have defined a new era in rheumatoid arthritis (RA) management but share the limitation of antagonising…
4
Mins
31 Jul 2018
Congress Feature from EULAR 2018
Building on last year’s launch, the EULAR ‘Don’t Delay, Connect Today’ campaign was a highlight of this year’s EULAR Congress. As part of EMJ’s…
Loading posts...
« Previous
1
…
62
63
64
65
66
…
83
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View